Category Archives: Patent Eligible Subject Matter

Prometheus Unbound – Are Methods Of Medical Treatment The Next “Targets”?

Posted on May 22, 2012 by Warren Woessner

In my March post “Unnatural Acts – Patenting Diagnostic Tests Post-Prometheus” I wrote: “I have been trying to formulate diagnostic claims that would pass muster post-Prometheus and I am having trouble. If a researcher discovers the marker, the researcher should … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | 2 Comments

Prometheus Q/A Results: Does Patent Eligibility Impact Biotech Research?

Posted on May 7, 2012 by Warren Woessner

A guest post from shareholder Robin Chadwick of SLW. A quick survey of folks who read this blog indicates that funding for 5 Buy Cheap Cialis Soft 0% of respondents’ R&D is affected by whether or not a project was … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Fed. Cir. Orders Briefing in Myriad Remand

Posted on May 1, 2012 by Warren Woessner

On April 30th, in response to the Supreme Court’s GVR of the Myriad appeal (AMP et al. are still trying to get the claims to isolated DNA molecules and the use of a transgenic cell comprising the BRCA1 gene to … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | 1 Comment

Prometheus Q/A – Which Side Are You On?

Posted on April 12, 2012 by Warren Woessner

A guest post from Robin Chadwick of SLW. During the three weeks since the Supreme Court ruled that certain diagnostic claims are not eligible for patenting, four other patent cases have been impacted by this ruling. The Court is shaping … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | 1 Comment